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BACKGROUND: The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated
patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We
hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.
METHODS: Patients with breast cancer were enroled in a trial of adjuvant AI therapy. Changes in pain and function during therapy were
assessed prospectively. We selected 30 cases with AIMSS and 22 controls without AIMSS, matched for demographics and prior
therapy. Serum samples collected at baseline and during treatment were assayed for multiple inflammatory cytokines and lipid
mediators using multiplex assays.
RESULTS: Before AI therapy, mean serum concentrations of 6 of 36 assayed factors were statistically significantly lower in cases than
controls (all Po0.003). No statistically significant changes during AI therapy relative to pre-treatment were observed between cases
and controls for any of the inflammatory markers tested.
CONCLUSION: AIMSS is probably not associated with a systemic inflammatory response. Pre-treatment cytokine levels may predict for
development of AIMSS.
British Journal of Cancer (2010) 103, 291–296. doi:10.1038/sj.bjc.6605768 www.bjcancer.com
Published online 6 July 2010
& 2010 Cancer Research UK
Keywords: aromatase inhibitor; arthralgia; breast cancer; cytokine
                                                            
Adjuvant endocrine therapy decreases mortality for women with
invasive hormone receptor (HR)-positive breast cancer (Peto et al,
2000; EBCTCG, 2005). The three third-generation aromatase
inhibitors (AIs) used in routine clinical practice in post-
menopausal women (anastrozole, letrozole, and exemestane;
Boccardo et al, 2005; Goss et al, 2005; Jakesz et al, 2005; Winer
et al, 2005; Coates et al, 2007; Coombes et al, 2007; Forbes et al,
2008; Mamounas et al, 2008) act by inhibiting the aromatase
enzyme, thereby substantially decreasing serum oestrogen con-
centrations (Geisler et al, 2002).
Aromatase inhibitor-associated musculoskeletal symptoms
(AIMSS), including arthralgias and myalgias, have been noted in
up to 50% of treated patients (Burstein and Winer, 2007; Crew
et al, 2007; Henry et al, 2008a,b). Severe toxicity resulted in a
greater than 10% treatment discontinuation rate in a recently
reported trial (Henry et al, 2008a). A variety of pharmacological
interventions to prevent or treat AIMSS have been largely
ineffective (Burstein and Winer, 2007; Crew et al, 2007; Henry
et al, 2008a,b). However, recent data from a large randomised
controlled trial demonstrated that development of AI-associated
joint pain might predict improved breast cancer outcomes (Cuzick
et al, 2008).
The aetiology of AIMSS remains undetermined. Clinical data
have not supported the hypothesis that a systemic inflammatory
process causes AIMSS (Henry et al, 2008b). However, imaging
studies have demonstrated the development of tenosynovitis in
patients treated with AIs (Morales et al, 2008), suggesting that
localised inflammation may occur.
Oestrogen is known to have a role in the immune system
(Carlsten, 2005). Inflammatory mediators, including interleukins
(ILs), interferons, and matrix metalloproteinases, have been
associated with changes in oestrogenic signalling (Straub, 2007).
Increases in pro-inflammatory cytokine levels, including those of
IL-1, tumour necrosis factor-alpha, and IL-6, can occur during
menopause (Pfeilschifter et al, 2002). Recent data have also
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sdemonstrated that lipid mediators may influence the action of
oestrogens (Sukocheva et al, 2009). Thus, multiple oestrogen-
dependent inflammatory mediators may be associated with the
development of a localised inflammatory process.
We therefore hypothesised that AIMSS may be associated with
alterations in serum concentrations of pro-inflammatory media-
tors. To test this hypothesis, we evaluated changes in serum
concentrations of multiple inflammatory molecules in subjects
enroled in a multicenter prospective clinical trial of AI therapy
MATERIALS AND METHODS
This is a case–control study embedded in a larger prospective
randomised controlled trial designated ELPh (Exemestane and
Letrozole Pharmacogenetics, NCT00228956), which has been
previously described in detail (Henry et al, 2008a).
Subjects
From August 2005 to October 2007, post-menopausal women with
stage 0–III breast cancer were recruited at the following
Consortium on Breast Cancer Pharmacogenomics (COBRA)
institutions: Indiana University Cancer Center, Sidney Kimmel
Comprehensive Cancer Center at The Johns Hopkins School of
Medicine, and the University of Michigan Comprehensive Cancer
Center. Subjects were ineligible if they had received prior AI
therapy. Prior tamoxifen and concurrent trastuzumab treatments
were permitted. All indicated surgery, radiation therapy, and
chemotherapy for breast cancer was completed before study
enrolment. The protocol was approved by the Institutional Review
Boards of all three participating study sites.
Study design
After providing written informed consent, subjects were randomly
assigned to two treatment groups: 25mg exemestane orally daily or
2.5mg letrozole orally daily for 2 years. At baseline and at 1, 3, 6,
and 12 months after AI therapy initiation, serum samples were
collected and subjects completed the two-page Health Assessment
Questionnaire and pain Visual Analog Scale (Bruce and Fries,
2003), a well-validated tool that has been used to evaluate the
functional status and pain of patients with rheumatic disorders.
Patients were referred for a detailed evaluation by a designated
rheumatologist at each site if they met pre-defined criteria for
increase in pain or decrease in functional status based on scores on
questionnaires (Henry et al, 2008a). In brief, subjects met criteria
for referral if they had (1) an increase in Health Assessment
Questionnaire score of 40.4 if their baseline score was 0–0.8; (2)
an increase in Health Assessment Questionnaire score of 40.2 if
their baseline score was 0.8–1.5; (3) a pain Visual Analog Scale
score above 5 if they had no pain at baseline; and/or (4) ‘much
worse’ or ‘very much worse’ pain based on the Self-rated Clinical
Global Impression Change Scale if they reported pain at the time of
AI initiation. Treating oncologists could also refer a subject
for rheumatologic evaluation if they felt that the subject had
AI-associated musculoskeletal symptoms even if the subject did
not meet the pre-defined criteria. At the time of evaluation, the
rheumatologists reported the symptom severity and impact on
patient function, as well as the apparent association between
symptoms and AI therapy (probably, possibly, or not related).
Selection of cases and controls
This hypothesis-generating case–control study was conducted
using samples and data from the ELPh trial. At the time of
selection of cases and controls, 260 subjects had completed
12 months of protocol-directed therapy. Cases were selected by the
coordinating center from those subjects who met pre-defined
criteria for rheumatologic evaluation within 12 months of AI
initiation and who were understood to have AI-associated
symptoms by the evaluating rheumatologist or treating oncologist.
Controls, defined as those subjects who did not meet criteria for
rheumatologic evaluation during the first 12 months of AI therapy,
were matched to the cases based on AI medication, age (±5 years),
prior chemotherapy (yes/no), prior tamoxifen (yes/no), and
ethnicity.
Quantification of serum inflammatory markers
We selected serum markers for analysis that had previously been
implicated in inflammatory responses, pain, arthritis, and
menopause (Pfeilschifter et al, 2002; Sommer and Kress, 2004;
Brennan and McInnes, 2008; Sukocheva et al, 2009). Serum
samples from the ELPh trial were stored at  701C until analysed;
all samples were assayed simultaneously in a blinded manner
according to manufacturer’s instructions. The inflammatory
markers listed in Supplementary Table 1 were assayed. Cytokine
and matrix metalloproteinase levels were measured using an
addressable laser bead multiplex assay (BMD, Paris, France) on a
Luminex S100 analyser (Luminex Corporation, Austin, TX, USA);
multiple proteins were detected simultaneously within a serum
sample (Stebbing et al, 2008; Bower et al, 2009). The results were
calculated using StarStation 2.0 software system (Applied Cyto-
metry Systems, Sheffield, UK). Ceramide and sphingosine-1-
phosphate were extracted from serum and quantified as previously
described (Folch et al, 1957; Liu et al, 2000; Bonhoure et al, 2006).
Statistical analyses
Statistical comparisons for each factor were performed by
comparing cases with controls. This approach maximised the
number of subjects in the analyses by allowing unpaired cases
and controls to be included. The non-parametric Mann–Whitney
U-test was used to compare case and control values for
categorical data, and the unpaired two-tailed t-test was used for
continuous data.
For continuous data, values were log-transformed before
analysis because they were frequently observed to be positively
skewed. This implies that proportional values are then the subject
of the analyses when changes are being examined, for example,
log(1 month value)–log(baseline value)¼log(1 month value/
baseline value). Results were summarised by back-transforming
the means and confidence interval values obtained from the
analyses on the log-transformed data. Continuous data were
analysed as categorical variables if a significant proportion of
values fell below the lower limit of detection for the individual
assay. Changes from baseline to 1 and 6 months were categorised
into four groups: an increase in score; no change in score; a
decrease but not below the limit of detection; and a decrease below
the limit of detection. These four categories were scored 1–4 and
this score was used for non-parametric statistical comparisons.
Subsequently, statistical comparisons were performed taking the
case and control pairings into account. The Wilcoxon signed rank
test was used for categorical data and the paired t-test was used for
continuous data.
All P-values are uncorrected for multiple comparisons. As this
was an exploratory study, a false discovery rate correction was
used. This approach is more appropriate to allow for multiple
testing rather than a family-wise error rate correction, such as a
Bonferroni correction. The former is less stringent and controls
the proportion of false positives (in this case 5%) in the tests
declared significant, rather than ensuring the probability that there
are any tests at all declared falsely significant is 5%. The
uncorrected P-value that corresponds to a false discovery rate of
5% in this study was P¼0.003.
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Patient characteristics
We selected 30 cases who enroled in the prospective ELPh trial and
who were referred for rheumatological evaluation because of
increased pain or worsened functional status during AI therapy.
One case did not meet the pre-defined criteria for referral based on
questionnaire data, but was diagnosed with AI-associated muscu-
loskeletal symptoms by her treating oncologist. Thirty matched
controls, who did not experience increased pain or worsened
functional status during AI therapy, were then selected. However,
eight controls were subsequently deemed ineligible because they
failed to complete 12 months of AI treatment for reasons
unrelated to musculoskeletal symptoms and therefore were not
included in any analyses. Baseline characteristics of the cases and
included controls are presented in Table 1. Approximately half of
cases and half of controls reported taking non-steroidal medica-
tions during study participation. Of the cases, 17 of 30 prematurely
discontinued study participation a median of 7.2 months
(range 2–19 mo) after enrolment because of arthralgias (n¼10),
carpal tunnel syndrome (n¼3), myalgias (n¼2), or fatigue/
insomnia (n¼2).
There was no statistically significant difference in pain severity
or functional status between cases and controls before the
initiation of AI therapy (data not shown). Pain severity was
statistically significantly different between cases and controls at
1, 3, and 6 months after treatment initiation. Functional status as
assessed using the Health Assessment Questionnaire instrument
was statistically significantly different between the two groups only
at the 6-month time point.
Baseline serum concentrations of multiple inflammatory
markers
Serum concentrations of baseline inflammatory markers from
cases were compared with those of controls. Not all samples were
assayed for all factors due to insufficient quantity of serum.
Baseline serum concentrations of fibroblast growth factor-basic,
IL-1 receptor-a, IL-12 p40, macrophage inflammatory protein-1a,
IL-1b, and IL-17 were statistically significantly lower in cases than
in controls (all Po0.003; Figure 1). At baseline, the mean serum
concentration of only one inflammatory marker, RANTES
(regulated upon activation, normal T cell expressed and secreted),
was higher in cases compared with controls (18344 vs
15721pgml
 1; P¼0.03) although the difference was not statisti-
cally significant when adjusted to avoid false discovery (see
Materials and Methods section). Results for all assayed cytokines
are provided in Supplementary Table 2.
Baseline serum concentrations of inflammatory factors
were also analysed in matched pairs of cases and controls. Similar
to the comparison of all cases vs all controls, there was a
statistically significant difference between matched cases and
controls for IL-17, IL-12 p40, and IP-10 (all Po0.003). In contrast,
two factors were present at higher concentrations in cases
compared with controls, although the differences were not
statistically significant when adjusted to avoid false discovery.
The ratio of matched cases to controls for RANTES was 1.22
(0.91–1.63; P¼0.01), and for matrix metalloproteinase-9 was 1.92
(1.16–3.17, P¼0.01). Levels of all other assayed factors were
unchanged or were higher in matched controls compared with
cases, but the differences were not statistically significant (data not
shown).
Change in serum inflammatory markers during AI therapy
Changes in serum inflammatory marker concentrations
during AI therapy relative to pre-treatment baseline were
assessed. Not all subjects had serum available at all time points,
including those who discontinued AI therapy before the 6-month
evaluation. A non-significant trend towards increased lipid
mediator S1P concentrations in cases (þ13%) and decreased
( 39%) S1P in controls was observed at the 6-month time
point compared with baseline (P¼0.08). There was also a trend
towards a greater percentage of cases with decreased serum
concentrations of IL-6 at the 6-month time point (54.2%)
compared with controls (25%; P¼0.08). Overall, there were no
statistically significant differences in change in serum
concentration of any inflammatory markers during AI therapy
when all cases were compared with all controls (data for all
cytokines at 1 and 6 months are provided in Supplementary Tables
3 and 4) or when matched cases and controls were analysed (data
not shown).
DISCUSSION
Musculoskeletal symptoms are increasingly recognised to be a
clinically significant toxicity of AI therapy, but the mechanism
underlying development of these symptoms remains unclear. As a
result, no clinical predictors of toxicity development have been
identified. In this case–control study, using samples from a
prospective trial, we describe differences in multiple pleiotropic
serum inflammatory factors in post-menopausal women who
develop this toxicity compared with those who remain asympto-
matic.
In contrast to our original hypothesis, in our study we observed
few differences in serum concentrations of inflammatory markers
during AI therapy between cases and controls, suggesting that
AIMSS is not due to a systemic inflammatory response. In
addition, the trend towards decreased IL-6 levels in affected
subjects, which is in contrast to published reports of the role of
IL-6 in inflammation (Choy and Panayi, 2001; Gabay, 2006),
further supports the lack of an inflammatory mechanism under-
lying AIMSS. These data are consistent with previously reported
findings of lack of anti-nuclear antibodies and/or elevated
erythrocyte sedimentation rate in affected patients (Azria et al,
2006; Henry et al, 2008a), but in contrast with results from a
prospective study of 24 patients with significant AI-associated pain
and concomitant elevations in anti-nuclear antibodies and
rheumatoid factor (Laroche et al, 2007).
Although no difference in cytokines during AI treatment was
detected between cases and controls, subjects who developed
AIMSS had lower concentrations of multiple cytokines before
treatment initiation, including both pro- and anti-inflammatory
molecules. This finding was unexpected. It is unlikely to be due to
prior chemotherapy or tamoxifen, or to specific AI medication, as
cases and controls were matched for both prior treatment regimen
and assigned AI. In addition, the pattern seems different from that
observed in other systemic inflammatory processes, such as
rheumatoid arthritis, tuberculosis, sarcoidosis, and multi-system
disorders such as multicentric Castleman’s disease (Bower et al,
2007, 2009; Stebbing et al, 2008).
Table 1 Subject characteristics
Characteristic Cases (n¼30) Controls (n¼22)
Median age (years, range) 56.9 (47–67) 58.4 (50–71)
Median weight (kg, range) 81.5 (55.8–150.6) 77.6 (57–108)
Median BMI (kgm
 2, range) 30.5 (22.3–48.5) 29.2 (21.0–38.7)
Prior chemotherapy 17 (56.7%) 13 (59.1%)
Prior taxane treatment 10 (34.5%)
a 7 (31.8%)
Prior tamoxifen treatment 15 (50%) 9 (40.9%)
Abbreviation: BMI¼body mass index.
aOne unknown.
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seldom report these musculoskeletal symptoms. One report noted
16% of anastrozole-treated patients with metastatic breast cancer
developed arthralgias, although only a minority developed severe
symptoms (Donnellan et al, 2001). One hypothesis is that patients
with ‘active cancer’ may have higher circulating levels of cytokines
before initiation of therapy, and therefore be less susceptible to
development of symptoms. Alternatively, less emphasis may be
placed on these symptoms in patients with other cancer-related
symptoms.
One limitation of this study is the focus on systemic as opposed
to local concentrations of inflammatory factors. Others have
suggested that local inflammatory processes may be occurring,
such as tenosynovitis at the wrist, as demonstrated using magnetic
resonance imaging (Morales et al, 2008). Therefore, future
mechanistic studies could be designed to investigate changes at
the local level.
Another limitation of this study is the small sample size and
large number of analysed factors. In addition, although it is
not unexpected that subjects may have to discontinue
AI therapy prematurely because of the development of AIMSS
(Henry et al, 2008a), a number of controls also discontinued
therapy before the 12-month time point for reasons unrelated to
arthralgias and had to be excluded from this analysis, as it was
unknown whether they would have developed AIMSS had they
continued study participation for the entire duration. This further
limited statistical power.
In summary, contrary to our initial hypothesis, we failed to
observe an association between AIMSS and a systemic inflam-
matory response after initiation of an AI. Therefore, if oestrogen
deprivation is the underlying cause of this musculoskeletal toxicity,
it may be inducing a localised inflammatory effect, such as in the
bone or tendon, rather than a global effect, such as the increase in
systemic inflammatory factors seen at the time of menopause.
Alternatively, AIMSS could be due to a non-inflammatory process.
Overall, these data suggest that AIMSS is distinct from other
rheumatologic conditions, and continued research into aetiologies
and management approaches is warranted.
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